Date: 2015-01-21
Type of information: Nomination
Compound:
Company: Medivir (Sweden)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 21, 2015, Medivir announced a reorganization of the management team in order to streamline and increase operational focus. After the change the company´s management team consists of 6 people, including the CEO, vs. previously 8 people. Two new functions are created: Strategic Business Development, which is a consolidation of Corporate Development and Business Development, and Finance & Administration, which is a consolidation of the current Finance & Administration function and Corporate Affairs & IR.Christine Lind has been recruited as new head of Strategic Business Development. New CFO, with responsibility also for IR, will be Ola Burmark. Christina Kassberg, Rein Piir, Paul Wallace and Håkan Wallin have chosen to leave the company by the end of February. The new organization will be effective on March 1, 2015.
Financial terms:
Latest news:
